Evidence map›Paper›PMID 39243982›Full record

ArticleJournal of substance use and addiction treatment2024

Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded program.

Hunter Spencer, Gillian Leichtling, Jane Babiarz, Christopher B Fox, Megan Herink, Joanna Cooper, Kelly Jones, Tonhi Gailey, Judith Leahy, Ryan Cook and 2 more

Abstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hunter SpencerOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America. Electronic address: spencerh@ohsu.edu.
Gillian LeichtlingComagine Health, Portland, OR, United States of America.
Jane BabiarzOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Christopher B FoxOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Megan HerinkOregon State University, College of Pharmacy, Corvallis, OR, United States of America.
Joanna CooperOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Kelly JonesOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Tonhi GaileyOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Judith LeahyOregon Health Authority, Behavioral Health Services, Health Systems Division, United States of America.
Ryan CookOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.
Andrew SeamanOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America; Central City Concern, Portland, OR, United States of America.
P Todd KorthuisOregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.

Funding

Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Oregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Transporting treatment effects from clinical trials to real-world populations with co-occurring opioid and stimulant use disordersK01DA055130 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI COOK, RYAN · 2022 to 2025
$714k
NCATS NIH HHS KL2 TR002370NIDA NIH HHS K01 DA055130NIDA NIH HHS UG1 DA015815NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

introductionThe opioid crisis and the hepatitis C virus epidemic perpetuate and potentiate each other in a syndemic with escalating morbidity. Policy-driven funding can help resolve the syndemic through collaborative solutions that rapidly translate evidence-based interventions into real-world applications.

methodsWe report development and programmatic evaluation of Peer-Assisted Telemedicine for Hepatitis C (PATHS), which utilizes State Opioid Response (SOR) funding to scale-up a positive randomized trial of peer-assisted telemedicine HCV treatment. PATHS employs staff within an academic medical center and partners with people with lived experience of drug use, "peers," to recruit rural-dwelling people who use drugs living with HCV. PATHS staff record patient data by abstracting clinical records or directly communicating with patients and peers. Peers are funded by a separate SOR-supported program administered through the state health authority. Peers support patients through HCV screening, treatment initiation via telemedicine, adherence, and cure.

resultsBetween March 2021 and June 2024, PATHS expanded to 18 of Oregon's 36 counties. In that time, PATHS diagnosed 198 rural PWUD with HCV. One hundred sixty-seven (84.3 %) linked to telemedicine and of these, 145 (86.8 %) initiated treatment. Of those who initiated treatment, 91 (62.8 %) completed treatment, of which 61 (67.0 %) are cured.

conclusionsBy rapidly translating a clinical innovation in HCV treatment to achieve highly effective real-world results, PATHS models how policy-driven funding can facilitate collaboration between community partners, academic medical centers, and state health departments to end the opioid-HCV syndemic.

Indexed as

Hepatitis CPeer GroupTelemedicineAdultFemaleHumansMaleMiddle AgedOpioid EpidemicOpioid-Related DisordersOregonProgram EvaluationRural PopulationHarm reductionHepatitis C virus (HCV)People who use drugs (PWUD)PolicyState Opioid Response

Identifiers

PMID39243982
PMCPMC11561891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.